Search

Your search keyword '"Lebbé, Céleste"' showing total 863 results

Search Constraints

Start Over You searched for: Author "Lebbé, Céleste" Remove constraint Author: "Lebbé, Céleste"
863 results on '"Lebbé, Céleste"'

Search Results

3. Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma

4. When to stop immunotherapy for advanced melanoma: the emulated target trials

5. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy

6. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024

7. Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma

8. Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database

11. Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.

12. Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy

13. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

14. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects

15. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

16. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023

17. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023

19. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials

22. Characteristics of circulating KSHV-infected viroblasts during active KSHV+ multicentric Castleman disease

24. Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort

26. CLAUDIUS Study: Risk of materno-fetal transmission of melanoma cells in pregnant women with high grade melanoma – A retrospective multicenter study and literature review

27. Immune-related generalised oedema – A new category of adverse events with immune checkpoint inhibitors

28. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial

29. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases

30. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022

31. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022

32. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022

35. Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort

37. Genomic profiling of a skin adnexal carcinomas cohort using a comprehensive high throughput sequencing approach

38. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

39. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis

41. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

42. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

43. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

44. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response

45. Hematological immune related adverse events after treatment with immune checkpoint inhibitors

49. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention

50. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment

Catalog

Books, media, physical & digital resources